Evidence map›Paper›PMID 34811696›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3.

X Xie, J Ji, X Chen, W Xu, H Chen, S Zhu, J Wu, Y Wu, Y Sun, W Sai and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Exosomes: Emerging Insights into the Progression of Pancreatic Cancer.International journal of biological sciences · 2024
    Review
  16. Review
  17. Review
  18. EVs vs. EVs: MSCs and Tregs as a source of invisible possibilities.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

X Xie *Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
J Ji *Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
X Chen *Office of Infection Management, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
W XuDepartment of Gastroenterology, Second People's Hospital of Nantong, Nantong, 226001, China.
H ChenOffice of Infection Management, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
S ZhuMedical School of Nantong University Oral Medicine, Nantong, 226001, Jiangsu, China.
J WuDepartment of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
Y WuDepartment of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
Y SunBlood Center of Jiangsu Province, Nanjing, 210000, Jiangsu, China.
W SaiResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
Z LiuDepartment of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
M XiaoDepartment of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China. xmb73@163.com.ORCID http://orcid.org/0000-0003-3372-1069
B BaoDepartment of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China. Bamboo1971@126.com.
Nantong University · CNJiangsu Province Blood Center · CN

Funding

jiangsu provincial key research and development program BE2019692Natural Science Foundation of Jiangsu Province BK20211105postdoctoral research foundation of china 2019M661909social development foundation of nantong city JCZ20065social development foundation of nantong city MS12020018social development foundation of nantong city MSZ19177social development foundation of nantong city MSZ20076the health project of jiangsu province H2019072
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignant tumors of the digestive system. Many patients are diagnosed at an advanced stage and lose eligibility for surgery. Moreover, there are few effective methods for treating pancreatic ductal cell carcinoma. Increasing attention has been given to microRNAs (miRNAs) and their regulatory roles in tumor progression. In this study, we investigated the effects of exosomes extracted from human umbilical cord mesenchymal stem cells (HUCMSCs) carrying hsa-miRNA-128-3p on pancreatic cancer cells.

methodsBased on existing experimental and database information, we selected Galectin-3, which is associated with pancreatic cancer, and the corresponding upstream hsa-miRNA-128-3p. We extracted HUCMSCs from a fresh umbilical cord, hsa-miRNA-128-3p was transfected into HUCMSCs, and exosomes containing hsa-miRNA-128-3p were extracted and collected. The effect of exosomes rich in hsa-miRNA-128-3p on pancreatic cancer cells was analyzed.

resultsThe expression of Galectin-3 in normal pancreatic duct epithelial cells was significantly lower than that in PDAC cell lines. We successfully extracted HUCMSCs from the umbilical cord and transfected hsa-miRNA-128-3p into HUCMSCs. Then we demonstrated that HUCMSC-derived exosomes with hsa-miRNA-128-3p could suppress the proliferation, invasion, and migration of PANC-1 cells in vitro by targeting Galectin-3.

conclusionHsa-miRNA-128-3p could be considered as a potential therapy for pancreatic cancer. We provided a new idea for targeted therapy of PDAC.

Indexed as

Carcinoma, Pancreatic DuctalExosomesGalectin 3HumansMesenchymal Stem CellsPancreatic NeoplasmsTumor Cells, CulturedUmbilical CordGalectin 3ExosomeGalectin-3Hsa-miRNA-128-3pHuman umbilical cord mesenchymal stem cellsPancreatic ductal cell carcinoma

Identifiers

PMID34811696
OpenAlexW3216645753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.